TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26993471

Group type: EXPERIMENTAL
Intervention: Fixed incentive condition (usual invitation letter, including a voucher for £10 if they attend their appointment)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Probabilistic incentive condition (invitation letter, including a voucher for a 1 in 100 chance of winning £1000 if they attend their appointment)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control condition (usual invitation letter)
Number of subjects: 1000
Study: 23981321

Group type: EXPERIMENTAL
Intervention: Word-learning training, 2-weekly sessions across 10 weeks
Number of subjects: 5
Study: 23163988

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 88
Study: 20812958

Group type: EXPERIMENTAL
Intervention: L-carnitine supplement (1000 mg/d for 12 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no L-carnitine supplement)
Number of subjects: 36
Study: 17926113

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Scleral Buckling
Number of subjects: 46
Study: 16369725

Group type: EXPERIMENTAL
Intervention: Weighted logistic regression approach to adjust odds ratios
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New diagnostic technique for hip BMD and deformity severity
Number of subjects: 0
Study: 12796586

Group type: EXPERIMENTAL
Intervention: PTFE patching
Number of subjects: 180

Group type: COMPARATOR
Intervention: Hemashield patching
Number of subjects: 180
Study: 10948088

Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐L‐arginine (L‐NMMA) (3 mg/kg per hour)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1 to 3 mg/h)
Number of subjects: 26

Group type: COMPARATOR
Intervention: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 26
Study: 8980592

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg over three days)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Maloprim (6.25 mg pyrimethamine + 50 mg dapsone for children under 10 years, and 12.5 mg pyrimethamine + 100 mg dapsone for children 10 or more years old as a single dose)
Number of subjects: 77
Study: 1419440

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 40

Group type: COMPARATOR
Intervention: Face mask and Guedel airway
Number of subjects: 40
Study: 3914621

Group type: COMPARATOR
Intervention: Daily administration of retinoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Administration of retinoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Folic acid administration
Number of subjects: 0
Study: 31580693

Group type: EXPERIMENTAL
Intervention: I-gel mask
Number of subjects: 200

Group type: COMPARATOR
Intervention: Baska mask
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both I-gel and Baska masks
Number of subjects: 200
Study: 28953669

Group type: EXPERIMENTAL
Intervention: Ultrasound group (ULS group; n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oxygenation group (OXY group; n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups after pulmonary recruitment
Number of subjects: 40
Study: 25395078

Group type: EXPERIMENTAL
Intervention: Ureteroscope‐assisted 'Mini‐Perc' technique
Number of subjects: 72

Group type: COMPARATOR
Intervention: Modified open surgery
Number of subjects: 72
Study: 24046526

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 122

Group type: COMPARATOR
Intervention: Modified supine position
Number of subjects: 122
Study: 23272437

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 90
Study: 18297248

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17219216

Group type: EXPERIMENTAL
Intervention: MDMA (75 and 50 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15378567

Group type: EXPERIMENTAL
Intervention: Short-term radiotherapy
Number of subjects: 1304

Group type: COMPARATOR
Intervention: Pre-existing mucinous carcinoma
Number of subjects: 1304
Study: 11993408

Group type: EXPERIMENTAL
Intervention: Potassium losartan 50 mg per day
Number of subjects: 19
Study: 9323736

Group type: EXPERIMENTAL
Intervention: Visual training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reading (placebo)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 8188888

Group type: EXPERIMENTAL
Intervention: Topical calcitriol (3 micrograms/gm) applied twice daily for 6 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Betamethasone dipropionate (500 micrograms/gm)
Number of subjects: 18
Study: 3796920

Group type: EXPERIMENTAL
Intervention: Vaginal administration of prostaglandin E1 analogue (ONO-802)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 121
Study: 30866893

Group type: EXPERIMENTAL
Intervention: HBV vaccination (94.2% reported vaccination; 4.7% with 2 doses, 58.1% with 3 doses, 37.2% took a booster)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Older age (OR=4.24), lack of HBV vaccination (OR=7.42), working in high HBV incidence province (OR=2.69)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Use of safety devices (SD) (86.3% usage)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Needle recapping (35.9% participants)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Under-reporting of sharp injuries (SIs) (80.0% incidents not reported)
Number of subjects: 306
Study: 30127247

Group type: EXPERIMENTAL
Intervention: EGCG (752 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (800 mg corn starch)
Number of subjects: 22
Study: 26961597

Group type: EXPERIMENTAL
Intervention: 15 mg of tranexamic acid (TXA) mixed in 100 mL normal saline
Number of subjects: 108

Group type: COMPARATOR
Intervention: 100 mL of normal saline
Number of subjects: 108
Study: 25200415

Group type: EXPERIMENTAL
Intervention: QGE031 (2 mg/kg)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Omalizumab
Number of subjects: 183

Group type: COMPARATOR
Intervention: QGE031 (0.1-10 mg/kg) or placebo (IV)
Number of subjects: 183

Group type: COMPARATOR
Intervention: QGE031 (0.2-4 mg/kg) or placebo (SC)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: QGE031 (10 mg/kg)
Number of subjects: 183
Study: 22265698

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4657

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4657
Study: 21166111

Group type: EXPERIMENTAL
Intervention: Once-daily Tacrolimus Extended Release (Tac ER)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Twice-daily Cyclosporine (CsA)
Number of subjects: 18
Study: 17934668

Group type: EXPERIMENTAL
Intervention: Supervised exercise three times per week for 20 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nutritional counseling and psychological support
Number of subjects: 40
Study: 16644634

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day for 12 weeks)
Number of subjects: 42
Study: 12048178

Group type: EXPERIMENTAL
Intervention: Covert orienting of attention paradigm in pointing task (valid, neutral, invalid conditions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covert orienting of attention paradigm in detection task (key-pressing)
Number of subjects: 0
Study: 9869176

Group type: EXPERIMENTAL
Intervention: Selenium (100 microg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg twice daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (non-supplemented)
Number of subjects: 36
Study: 7637854

Group type: EXPERIMENTAL
Intervention: Serial Reaction Time (SRT) task
Number of subjects: 21
Study: 2517495

Group type: EXPERIMENTAL
Intervention: Oxindanac 200 mg thrice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol 1 g thrice daily (positive control)
Number of subjects: 0
Study: 194506

Group type: EXPERIMENTAL
Intervention: EG626 (cAMP phosphodiesterase inhibitor)
Number of subjects: 23
Study: 31515921

Group type: EXPERIMENTAL
Intervention: Oral IgG
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-oral IgG
Number of subjects: 16
Study: 28719709

Group type: EXPERIMENTAL
Intervention: Received the book for free
Number of subjects: 112

Group type: COMPARATOR
Intervention: Recommended to purchase the book
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: General cohort
Number of subjects: 112
Study: 27077121

Group type: EXPERIMENTAL
Intervention: VIS410 (2 mg/kg - 50 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: VIS410 (30 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: VIS410 (50 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: VIS410 (2% coverage)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: VIS410 (6% coverage)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: VIS410 (2% coverage for elderly)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: VIS410 (6% coverage for elderly)
Number of subjects: 41
Study: 24416316

Group type: EXPERIMENTAL
Intervention: On-Site Support (OSS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (arm B)
Number of subjects: 36
Study: 22012970

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 19254816

Group type: EXPERIMENTAL
Intervention: Yacon syrup (0.14 g fructooligosaccharides/kg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Yacon syrup (0.29 g fructooligosaccharides/kg/day)
Number of subjects: 100
Study: 17197807

Group type: EXPERIMENTAL
Intervention: CD4 cell count and plasma HIV‐1 RNA (pVL)‐guided treatment interruptions (GTI)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard antiretroviral therapy (control group)
Number of subjects: 201
Study: 15976210

Group type: EXPERIMENTAL
Intervention: 7.5 mg of hyperbaric ropivacaine 0.5% (group Ropi‐7.5, n = 31)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 5 mg of hyperbaric levobupivacaine 0.5% (group Levo‐5, n = 30)
Number of subjects: 91

Group type: COMPARATOR
Intervention: 7.5 mg of hyperbaric levobupivacaine 0.5% (group Levo‐7.5, n = 30)
Number of subjects: 91
Study: 16900603

Group type: EXPERIMENTAL
Intervention: Accommodative intraocular lenses (IOLs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monofocal intraocular lenses (IOLs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multifocal intraocular lenses (IOLs)
Number of subjects: 0
Study: 10528287

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) administered orally at 1 g twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Systemic cyclosporin A (CSA) with dosage varying between 100 and 500 mg daily based on blood trough levels of 120-150 ng/ml
Number of subjects: 16
Study: 8895005

Group type: EXPERIMENTAL
Intervention: Fixed dose interferon-alpha 2b 3 MU thrice weekly for 1 year
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Titrated dose interferon starting at 5 MU thrice weekly for 1 year
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 95
Study: 2071726

Group type: EXPERIMENTAL
Intervention: Mediation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Litigation
Number of subjects: 0
Study: 6133481

Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg and 50 mg
Number of subjects: 94
Study: 31082669

Group type: EXPERIMENTAL
Intervention: Combination treatment (Radium-223 55 kBq/kg every six weeks × 5 doses plus docetaxel 60 mg/m2 q3w × 10 doses)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Docetaxel alone (75 mg/m2 every 3 weeks)
Number of subjects: 53
Study: 29605498

Group type: EXPERIMENTAL
Intervention: Delayed-decision group (surgery assessment at 14 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard-care group (surgery assessment at 8 weeks)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Delayed-decision group
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard-care group
Number of subjects: 119
Study: 27037563

Group type: EXPERIMENTAL
Intervention: Single-incision tension-free vaginal tape (Ajust™)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape obturator (TVT-O)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 25213339

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 24
Study: 22267599

Group type: EXPERIMENTAL
Intervention: Azithromycin (Azi) 250 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 20123314

Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacing (RAP) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18347115

Group type: EXPERIMENTAL
Intervention: Figure-of-eight technique
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prism method
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water volumetry
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 10
Study: 15833782

Group type: EXPERIMENTAL
Intervention: Diphenhydramine-morphine mixture (4.8:1 ratio)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Diphenhydramine-morphine mixture (1.2:1 ratio)
Number of subjects: 112
Study: 12202647

Group type: EXPERIMENTAL
Intervention: 1000-ppm fluoride dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2500-ppm fluoride dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional increment analysis (CVA & FOTI at D(3) threshold + radiography)
Number of subjects: 0
Study: 10595609

Group type: EXPERIMENTAL
Intervention: Hand-sewn anastomosis
Number of subjects: 41

Group type: COMPARATOR
Intervention: Stapled anastomosis
Number of subjects: 41
Study: 8607681

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Aprotinin (Control)
Number of subjects: 0
Study: 1875405

Group type: EXPERIMENTAL
Intervention: Therapist-supported maintenance condition
Number of subjects: 32

Group type: COMPARATOR
Intervention: Minimal contact maintenance condition (Control)
Number of subjects: 32
Study: 31446213

Group type: EXPERIMENTAL
Intervention: Olaparib monotherapy (300 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy treatment of physician's choice (TPC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study: 29465210

Group type: EXPERIMENTAL
Intervention: Remaxol included in infusion therapy before anesthesia
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group without antihypoxants
Number of subjects: 48
Study: 26072359

Group type: EXPERIMENTAL
Intervention: Worth the Walk intervention (hour-long sessions twice weekly for four weeks)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wait-list control group (no immediate intervention)
Number of subjects: 240
Study: 23208880

Group type: EXPERIMENTAL
Intervention: YF vaccine and Ig
Number of subjects: 80

Group type: COMPARATOR
Intervention: YF vaccine and saline placebo
Number of subjects: 80
Study: 21802442

Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine (0, 5, 10, 20 and 30 mg) during atomoxetine maintenance (80 mg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine during atomoxetine maintenance (80 mg/day)
Number of subjects: 7
Study: 19608354

Group type: EXPERIMENTAL
Intervention: Bupropion combined with cognitive behavioral therapy and contingency management
Number of subjects: 60
Study: 17051359

Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 2643

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 2643
Study: 15139054

Group type: COMPARATOR
Intervention: Trastuzumab alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus docetaxel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Docetaxel (30 mg/m2 weekly for 6 weeks)
Number of subjects: 100
Study: 11323146

Group type: EXPERIMENTAL
Intervention: Failure feedback
Number of subjects: 76

Group type: COMPARATOR
Intervention: Success feedback
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pain-related fear
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pre-lifting pain
Number of subjects: 76
Study: 9135354

Group type: EXPERIMENTAL
Intervention: Sevoflurane and nitrous oxide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isoflurane and nitrous oxide
Number of subjects: 80
Study: 7896588

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3583091

Group type: EXPERIMENTAL
Intervention: DA agonists (DA, L-dopa, L-dopa plus carbidopa, nomifensine, amphetamine)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DA and amphetamine
Number of subjects: 6
Study: 31034255

Group type: EXPERIMENTAL
Intervention: Patient-oriented education (POE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-oriented education (POE) and visual aid intervention (wrist band)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (POE and WB)
Number of subjects: 60
Study: 28422514

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25640832

Group type: EXPERIMENTAL
Intervention: Fast Track intervention (10 years of treatment with various services)
Number of subjects: 891

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 891
Study: 23131462

Group type: COMPARATOR
Intervention: 2000 IU/d vitamin D
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D
Number of subjects: 257
Study: 21455085

Group type: EXPERIMENTAL
Intervention: Infraclavicular continuous peripheral nerve block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supraclavicular continuous peripheral nerve block
Number of subjects: 60
Study: 19660594

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT)
Number of subjects: 0
Study: 16819382

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve supplementation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (without supplementation)
Number of subjects: 19
Study: 15769695

Group type: EXPERIMENTAL
Intervention: Heparin Management Test (HMT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Activated Coagulation Time (ACT)
Number of subjects: 38
Study: 11116238

Group type: EXPERIMENTAL
Intervention: Clonidine (5 microg/kg orally 60 min before surgery)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no clonidine premedication)
Number of subjects: 74
Study: 9399319

Group type: EXPERIMENTAL
Intervention: 1000‐Hz pure tone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: narrow band noise (700‐1300 Hz band width)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: broad band noise (100‐10,000 Hz band width)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rock music
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: babble speech
Number of subjects: 30
Study: 8395557

Group type: EXPERIMENTAL
Intervention: PVnRT‐PCR
Number of subjects: 159

Group type: COMPARATOR
Intervention: Cell culture and serology
Number of subjects: 159
Study: 2941141

Group type: EXPERIMENTAL
Intervention: Schizophyllan (SPG)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control
Number of subjects: 220
Study: 31393573

Group type: EXPERIMENTAL
Intervention: Statin-treated patients with elevated Lp(a)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Statin-treated patients with normal Lp(a)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 27760084

Group type: EXPERIMENTAL
Intervention: Gua sha therapy plus conventional treatment for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Conventional treatment alone)
Number of subjects: 80
Study: 25925031

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia with dexmedetomidine, lidocaine, and propofol infusions (Group DL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Opioid-based anesthesia with remifentanil and propofol infusions (Group RF)
Number of subjects: 80
Study: 23921331

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 6 lumbar facet joints with triamcinolone hexacetonide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular injection of triamcinolone acetonide at 6 lumbar paravertebral points
Number of subjects: 60
Study: 21600658

Group type: EXPERIMENTAL
Intervention: Medications
Number of subjects: 607

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 607
Study: 19384786

Group type: EXPERIMENTAL
Intervention: Avastin (1.25 mg in 0.05 mL) every six weeks
Number of subjects: 672

Group type: COMPARATOR
Intervention: Lucentis (0.05 mg in 0.05 mL) every four weeks
Number of subjects: 672
Study: 17040419

Group type: EXPERIMENTAL
Intervention: Aligning prism of 2Delta and above for exophoria
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control lens
Number of subjects: 80
Study: 15286056

Group type: COMPARATOR
Intervention: Topical NSAIDs
Number of subjects: 0
Study: 11431744

Group type: EXPERIMENTAL
Intervention: 3 MU IFN-alpha2b 3 times a week plus ribavirin 1,000 mg/d for 12 months
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: 5 MU IFN-alpha2b 3 times a week plus ribavirin for 12 months
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: 3 MU IFN-alpha2b 3 times a week plus ribavirin for 6 months
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: 5 MU IFN-alpha2b 3 times a week plus ribavirin for 6 months
Number of subjects: 594

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 594